Free shipping on all orders over $ 500

PF06650833 (Zimlovisertib)

Cat. No. M8100
PF06650833 (Zimlovisertib) Structure
Synonym:

Zimlovisertib; PF 6650833

Size Price Availability Quantity
10mM*1mL in DMSO USD 80  USD80 In stock
1mg USD 35  USD35 In stock
5mg USD 75  USD75 In stock
10mg USD 135  USD135 In stock
50mg USD 600  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PF06650833 is an inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4). IRAK4 kinase is important in innate immunity, involved in initiating signaling from Toll-like receptors and members of th einterleukin-1 receptor family. IRAK4 kinase is an attractive target for the treatment of various diseases associated with deregulated inflammation, such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and systemic lupus erythematosus. PF06650833 has been investigated for treatment of lupus.

Chemical Information
Molecular Weight 361.37
Formula C18H20FN3O4
CAS Number 1817626-54-2
Solubility (25°C) DMSO ≥ 20 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Satomi Matsuoka, et al. Myeloid differentiation factor 88 signaling in donor T cells accelerates graft- versus-host disease

[2] Spencer I Danto, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

[3] Chao-Yang Lai, et al. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation

Related IRAK Products
BIO-7488

BIO-7488 is a potent, selective, oral active and CNS-penetrant IRAK4 inhibitor, with IC50 values of 0.6 nM and >30 μM for IRAK4 and hERG, respectively.

IRAK4-IN-22

IRAK4-IN-22 is an orally potent and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively.In addition, IRAK4-IN-21 potently inhibits the production of IL-23 (IC50=0.10 µM), which may be useful in studies related to autoimmune diseases such as plaque psoriasis and psoriasis vulgaris. arthritis).

HS271

HS271 is an orally potent and selective IRAK4 inhibitor with an IC50 value of 7.2 μM. In addition, HS271 has superior in vitro enzymatic and cellular activities.

PROTAC IRAK4 degrader-3

PROTAC IRAK4 degrader-3 is a von Hippel-Lindau based IRAK4 degrader PROTAC.

IRAK inhibitor 4 (trans)

IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4 and a potent inhibitor of IRAK4.

  Catalog
Abmole Inhibitor Catalog




Keywords: PF06650833 (Zimlovisertib), Zimlovisertib; PF 6650833 supplier, IRAK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.